Skip to main content
SpringerLink
Log in

Acute leukemia following treatment of malignant glioma

  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

We report two patients with acute myeloid leukemia (AML) following therapy for malignant glioma; one was a young women treated heavily with alkylating agents for glioblastoma and the other a young man treated with high doses of procarbazine, lomustine, and vincristine (PCV) for anaplastic astrocytoma. We found 26 other examples of therapy related leukemia in adult and pediatric brain tumor patients. Including our two, there were 12 patients with malignant glioma; median interval from treatment to diagnosis of AML was 31 months. Nine adult malignant glioma patients all received nitrosoureas, some as the sole form of chemotherapy. No definite cases occurred after radiotherapy alone.

Based upon analogy with other cancers, the cumulative dose of chemotherapy, especially alkylating agents, is the major risk factor for development of secondary AML. Agents implicated include carmustine (BCNU), lomustine (CCNU), and procarbazine. Conventional radiotherapy appears not to confer additional risk. Progressive macrocytosis, early dose reductions for thrombocytopenia, and refractory anemia may provide early diagnostic clues. Current glioma therapy is leukemogenic but the number of patients who survive the interval required to induce AML is small; nevertheless, the identification of chemosensitive types of glioma, and subgroups of patients who derive the most benefit from chemotherapy, may result in increasing numbers of patients at risk of long term complications. If regimens such as PCV continue to prove valuable in neuro-oncology the risk of leukemia will require integration into the clinical decision process. A search for more effective therapy with minimal mutagenicity remains critical.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Biti G, Cellai E, Magrini SM, Papi MG, Ponticelli P, Boddi V: Second solid tumors and leukemia after treatment for Hodgkin's disease: an analysis of 1121 patients from a single institution. Int J Rad Oncol Biol Phys 29: 25-31, 1994

    Google Scholar 

  2. Henry-Amar M, Dietrich P-Y: Acute leukemia after the treatment of Hodgkin's disease. Hematol Oncol Clin N Amer 7: 369-387, 1993

    Google Scholar 

  3. Tester WJ, Kinsella TJ, Waller B, Makuch RW, Kelley PA, Glatstein E, De Vita VT: Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol 2: 762-769, 1984

    PubMed  Google Scholar 

  4. Valagussa P: Second neoplasms following treatment of Hodgkin's disease. Curr Opin Oncol 8: 805-811, 1993

    Google Scholar 

  5. Levine EG, Bloomfield CD: Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Sem Oncol 19: 47-84, 1992

    Google Scholar 

  6. Boice JD Jr, Greene MH, Killen JY Jr: Ellenberg SS, Kechn RJ, McFadden E, Chen TT, Fraumeni JF Jr: Leukemia and preleukemia after adjuvant treatment of gastrointestinal cancer with semustine (methyl-CCNU). N Engl J Med 309: 1079-1084, 1983

    PubMed  Google Scholar 

  7. Bokemeyer C, Schmoll H-J, Kuczyk MA, Beyer J, Siegart W: Risk of secondary leukemia following high cumulative doses of Etoposide during chemotherapy for testicular cancer. J Natl Cancer Inst 87: 58-60, 1995

    PubMed  Google Scholar 

  8. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, Schwartz AG, Weyer P, Moloney WC, Hoover RN: Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 326: 1745-1751, 1992

    PubMed  Google Scholar 

  9. Demuynck H, Verhoef GEG, Zachee P, Vandenberghe P, Van Orshoven A, Paridaens R, Samson I, Boogaerdts: Therapy-related acute myeloid leukemia with t(8;16)(p11;p13) following anthracycline-based therapy for nonmetastatic osteosarcoma. Cancer Genet Cytogenet 82: 103-105, 1995

    PubMed  Google Scholar 

  10. Hahn P, Nelson N, Baral E: Leukemia in patients with breast cancer following adjuvant chemotherapy and/or postoperative radiation therapy. Acta Oncol 33: 599-602, 1994

    PubMed  Google Scholar 

  11. Pederson-Bjergaard J, Osterlind K, Hansen M, Philip P, Pedersen AG, Hansen HH: Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung. Blood 66: 1393-1397, 1985

    PubMed  Google Scholar 

  12. Cohen RJ, Wiernik PH, Walker MD: Acute nonlymphocytic leukemia associated with nitrosourea chemotherapy: report of two cases. Cancer Treat Rep 60: 1257-1261, 1976

    PubMed  Google Scholar 

  13. Robustelli della Cuna GR, Paoletti P, Bernardo G, Knerich R, Butti G, Cuzzoni Q: Clinical toxicity of combined modality treatment of nitrosourea derivatives for central nervous system tumors. Neurosurgery 11: 408-411, 1982

    PubMed  Google Scholar 

  14. Genot J-Y, Krulik M, Poisson M, Van Efferterre R, Renoux M, Audebert AA, Canuel C, Smadja N, Debray J: Two cases of acute leukemia following treatment of malignant glioma. Cancer 52: 222-226, 1983

    PubMed  Google Scholar 

  15. Greene MH, Bice JD Jr, Strike TA: Carmustine as a cause of acute nonlymphocytic leukemia [letter]. N Engl J Med 313: 579, 1985

    Google Scholar 

  16. Heimdal K, Evensen SA, Fossa SD, Hirschberg H, Langholm R, Brogger A, Moller P: Karyotyping of a hematologic neoplasia developing shortly after treatment for cerebral extragonadal germ cell tumor. Cancer Genet Cytogenet 57: 41-46, 1991

    PubMed  Google Scholar 

  17. Hildebrand J, Malarme M, Flament-Durand J, Struckmans P: Acute nonlymphoblastic leukemia in a patient treated for brain tumor. Arch Neurol 39: 664-665, 1982

    PubMed  Google Scholar 

  18. Kempin S, Sundaresan N, Shapiro WB, Arlin Z, Acute nonlymphocytic leukemia following treatment of malignant glioma. Report of two cases. J Neurosurg 60: 1287-1290, 1984

    PubMed  Google Scholar 

  19. Krywicki R, Bowen K, Anderson L, Garland D, Cobb P, Jenkins T, O'Rourke T: Mixed-lineage acute myeloid leukemia associated with a suprasellar dysgerminoma. Am J Clin Oncol 18: 83-86, 1995

    PubMed  Google Scholar 

  20. Osband M, Cohen H, Cassady R, Jaffe N: Severe and protracted bone marrow dysfunction following long-term therapy with methyl-CCNU [abstract]. Proc Am Soc Clin Oncol 18: 303, 1977

    Google Scholar 

  21. Baram TZ, van Eys J, Dowell RE, Cangir A, Pack B, Bruner JM: Survival and neurologic outcome of infants with medulloblastoma treated with surgery and MOPP chemotherapy. Cancer 60: 173-177, 1987

    PubMed  Google Scholar 

  22. Blatt J, Penchansky L, Phebus C, Horn M: Leukemia in a child with a history of medulloblastoma. Ped Hematol Oncol 8: 77-82, 1991

    Google Scholar 

  23. Goffman TE, Woo SY, Manz H, McCullough D, Sinks LF, Chun BK, Miller RW: Ependymoma, glioblastoma, and acute leukemia in a child. Med Ped Oncol 11: 130-133, 1983

    Google Scholar 

  24. Hayani A, Mahoney DH Jr, Taylor LD: Therapy-related myclodysplastic syndrome in children with medulloblastoma following MOPP chemotherapy. J Neuro-Oncol 14: 57-62, 1992

    Google Scholar 

  25. Nora A, Heideman R, Peakman D, Morse H: Cytogenetic studies in an acute leukemia patient following cerebellar astrocytoma. Human Genet 50: 157-161, 1979

    Google Scholar 

  26. Pai MRSM, Advani SH, Gopal R, Nair CN, Saikai T, Kamat DM: Acute leukemia following malignant ependymoma: a case report. J Surg Oncol 29: 1-4, 1985

    PubMed  Google Scholar 

  27. Pui C-H, Hancock ML, Raimondi SC, Head DR, Thompson E, Wilimas J, Kun LE, Bowman LC, Crist WM, Pratt CB: Myeloid neoplasia in children treated for solid tumours. Lancet 336: 417-421, 1990

    PubMed  Google Scholar 

  28. Perilongo G, Felix CA, Meadow AT, Nowell P, Biegel J, Lange BJ: Sequential development of Wilms tumor, T-cell acate lymphoblastic leukemia, medulloblastoma and myeloid leukemia in a child with type 1 neurofibromatosis: A clinical and cytogenetic case report. Leukemia 7: 912-915, 1993

    PubMed  Google Scholar 

  29. Redman GP, Shu S, Norris D: Leukemia and growth hormone [letter]. Lancet 1(8595): 1159-1160, 1988

    PubMed  Google Scholar 

  30. Sasaki U, Hara M, Watanabe S: Occurrence of acute lymphoblastic leukemia in a boy treated with growth hormone for growth retardation after irradiation to the brain tumor. Jpn J Clin Oncol 18: 81-84, 1988

    PubMed  Google Scholar 

  31. Sayli T, Cemeroglu AP, Tuncer AM, Gurgey A: Acute lymphoblastic leukemia following optic glioma treated by radiotherapy and surgery. Acta Pacdiatr 82: 327-328, 1993

    Google Scholar 

  32. Vogl SE: Acute leukemia complicating treatment of glioblastoma multiforme. Cancer 41: 333-336, 1978

    PubMed  Google Scholar 

  33. Saleman M: Survival in glioblastoma: historical perspective. Neurosurgery 7: 435-439, 1980

    PubMed  Google Scholar 

  34. Chandler K, Prados MD, Malec M, Wilson CB: Long-term survival in patients with glioblastoma multiforme. Neurosurgery 32: 716-720, 1993

    PubMed  Google Scholar 

  35. Saleman M, Scholtz, Kaplan RS, Kuik S: Long-term survival in patients with malignant astrocytoma. Neurosurgery 34: 213-220, 1994

    PubMed  Google Scholar 

  36. Cairncross JG, Macdonald DR, Ramsay DA: Aggressive oligodendroglioma: a chemosensitive tumor. Neurosurgery 31: 78-82, 1992

    PubMed  Google Scholar 

  37. Cairncross G, Macdonald D, Ludwin S, Lee D, Caseino T, Bucker J, Fulton D, Dropcho E, Stewart D, Schold C Jr, Wainman N, Eisenhauer for the National Cancer Institute of Canada Clinical Trials Group' Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol 12: 2013-2021, 1994

    PubMed  Google Scholar 

  38. Mason WP, Krol GS, DeAngelis LM: Low-grade oligodendroglioma responds to chemotherapy. Neurology 46: 203-207, 1996

    PubMed  Google Scholar 

  39. Levin VA, Silver P, Hannigan J, Wara WM, Gutin PH, Davis RL, Wilson CB: Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vineristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys 18: 321-324, 1990

    Google Scholar 

  40. Fine HA: The basis of current treatment recommendations for malignant glioma. J Neuro-Oncol 20: 111-120, 1994

    Google Scholar 

  41. Gerson SL: Molecular epidemiology of therapy-related leukemia. Curr Opin Oncol 5: 136-144, 1993

    PubMed  Google Scholar 

  42. Groupe Français de Cytogénétique Hématologique: Acute leukemia treated with intensive chemotherapy in patients with a history of previous chemo and/or radiotherapy: Prognostic significance of karyotype and preceding myclodysplastic syndrome. Leukemia 8: 87-91, 1994

    Google Scholar 

  43. Le Beau MM, Albain KS, Larson RA, Vardiman JW, Davis EM, Bough RR, Golomb HM, Rowley JD: Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: Further evidence for characteristic abnormalities of chromosomes no 5 and 7. J Clin Oncol 4: 325-345, 1986

    PubMed  Google Scholar 

  44. Tsui L-C, Farrall M, Donis-Keller H: Report of the committee on the genetic constitution of chromosomes 7 and 8. Human Gene mapping 10. Cytogenet Cell Genet 51: 166-201, 1989

    PubMed  Google Scholar 

  45. Le Beau MM, Lemons RS, Espinosa R III, Larson RA, Arai N, Rowley JD: Interleukin-4 and interleukin-5 map to human chromosome 5 in a region encoding growth factors and receptors and are deleted in myeloid leukemias with a del (5q). Blood 73: 647-650, 1989

    PubMed  Google Scholar 

  46. Wong AJ, Zoltick PW, Moscattello DK: The molecular biology and molecular genetics of astrocytic neoplasms. Sem Oncol 21: 139-148, 1994

    Google Scholar 

  47. Bigner SH, Mark J, Burger PC, Mahaley MS Jr, Bullard DE, Muhlbaier LH, Bigner DD: Specific chromosomal abnormalities in malignant human gliomas. Cancer Res 48: 405-411, 1988

    PubMed  Google Scholar 

  48. Valagussa S, Santoro A, Fossati-Bellani F, Banfi A, Bonadonna G: Secondary acute leukemia and other malignancies following treatment for Hodgkin's disease. J Clin Oncol 4: 830-837, 1986

    PubMed  Google Scholar 

  49. Clive D, Truner N, Krehl R: Procarbazine is a potent mutagen at the heterozygous thymidine kinase locus of mouse lymphoma assay. Mutagenesis 3: 83-87, 1988

    PubMed  Google Scholar 

  50. Sieber SM, Correa P, Dalgard DW, Adamson RH: Carcinogenic and other adverse effects of procarbazine in nonhuman primates. Cancer Res 38: 2125-2134, 1978

    PubMed  Google Scholar 

  51. O'Gara RW, Adamson RH, Kelly MG, Dalgard DW: Neoplasms of the hematopoietic system in nonhuman primates: report of one spontaneous tumor and two leukemias induced by procarbazinc. J Natl Cancer Inst 46: 1121-1130, 1971

    PubMed  Google Scholar 

  52. Shulman LN: The biology of alkylating-agent cellular injury. Hematol Oncol Clin N Amer 7: 325-335, 1993

    Google Scholar 

  53. Nichols CR, Roth BJ, Heerema N, Griep J, Tricot G: Hematologic neoplasia associated with primary mediastinal germ cell tumors. N Engl J Med 322: 1425-1429, 1990

    PubMed  Google Scholar 

  54. Levin VA, Edwards MS, Wright DC, Seager ML, Schimberg TP, Townsend JJ, Wilson CB: Modified procarbazine, CCNU, and vineristine (PCV-3) combination chemotherapy in the treatment of malignant primary brain tumors. Cancer Treat Rep 64: 237-241, 1980

    PubMed  Google Scholar 

  55. Ballen KK, Antin JH: Treatment of therapy-related acute myclogenous leukemia and myelodysplastic syndromes. Hematol Oncol Clin N Amer 7: 477-493, 1993

    Google Scholar 

  56. Hess CF, Kortmann RD, Schmidberger II, Bamberg M: How relevant is secondary leukemia for initial treatment selection in Hodgkin's disease? Eur J Cancer 30A: 1441-1447, 1994

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Divisions of Neurology, Duke University Medical Center, Durham, NC, USA

    James R. Perry

  2. Divisions of Neurology, Duke University Medical Center, Durham, NC, USA

    Mark T. Brown

  3. Divisions of Medical Oncology, Duke University Medical Center, Durham, NC, USA

    Jon P. Gockerman

Authors
  1. James R. Perry
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mark T. Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jon P. Gockerman
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Perry, J.R., Brown, M.T. & Gockerman, J.P. Acute leukemia following treatment of malignant glioma. J Neurooncol 40, 39–46 (1998). https://doi.org/10.1023/A:1006175831785

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006175831785

Search

Navigation